How New Jersey Resources’ 31st Straight Dividend Hike Could Affect NJR Investors

• New Jersey Resources’ board of directors recently approved an increase in the quarterly dividend rate to US$0.475 per share, effective October 1, 2025, marking the 31st consecutive annual dividend increase since the company’s inception in 1952.
• This move underscores the company’s enduring emphasis on shareholder returns, even as its executive team expands with the upcoming addition of Amy B. Mansue to the board this November.
• We’ll explore how New Jersey Resources’ continued dividend growth strengthens its investment narrative amid evolving energy sector priorities.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

New Jersey Resources Investment Narrative Recap

To own shares in New Jersey Resources, investors need confidence in the company’s ability to sustain stable, long-term natural gas demand while capitalizing on population growth and energy efficiency programs. The recent dividend increase and board appointment, while furthering a track record of shareholder focus, have little immediate effect on the most pressing challenge: potential headwinds from regulatory or policy shifts affecting rate recovery and capex approvals that could weigh on near-term cash flow and margins.

The latest dividend hike to US$0.475 per share, effective October 2025, stands out, highlighting the company’s continued intent to return value to shareholders amid slow sector growth projections. This move reinforces the dividend’s consistency as a near-term catalyst, even as New Jersey Resources faces evolving sector risks and questions over long-term support for natural gas infrastructure.

However, investors should weigh the fact that, despite continued dividend growth, future state or federal policy changes targeting electrification could...

Read the full narrative on New Jersey Resources (it's free!)

New Jersey Resources is projected to reach $2.1 billion in revenue and $399.3 million in earnings by 2028. This outlook reflects a 0.1% annual decrease in revenue and a $12.4 million decline in earnings from the current $411.7 million.

Uncover how New Jersey Resources' forecasts yield a $53.57 fair value, a 13% upside to its current price.

Exploring Other Perspectives

All ten Simply Wall St Community fair value estimates for NJR cluster at US$53.57, signaling consensus before this month’s announcements. But with policy uncertainty looming, your outlook may differ considerably from others’ interpretations of future growth drivers.

Explore another fair value estimate on New Jersey Resources - why the stock might be worth as much as 13% more than the current price!

Build Your Own New Jersey Resources Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your New Jersey Resources research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free New Jersey Resources research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate New Jersey Resources' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com